A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours.

Trial Profile

A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Topotecan (Primary) ; Pazopanib
  • Indications Neuroblastoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms TOPAZ
  • Most Recent Events

    • 10 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by National Cancer Institute of Canada record.
    • 21 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top